ESMO Press Office

The ESMO Press Office welcomes media professionals interested in reporting on cancer.

For enquiries please contact us on:
media@esmo.org

ESMO 2019 640x90 Hashtag
Press & Media Centre and Filming Area – Access and facilities

The ESMO 2019 Press & Media Centre Is located in Hall CC3 of Fira Barcelona. It features a dedicated entrance - EAST ENTRANCE (Carrer de la Botànica) - different from the main registration entrance and easily reachable from the metro station Fira.

Badge collection and onsite accreditations will be dealt with by the staff in the Press & Media Centre.

Click on image to enlarge map

Blackout times

During Blackout times any media activity initiated by third parties is not allowed.

Day Time
27 September 2019 10:15-18:30
28 September 2019 08:00-18:30
29 September 2019 08:00-18:30
30 September 2019 08:00-18:30
1 October 2019 09:00-12:30
Publication schedule for accepted abstracts
  1. Abstracts accepted for presentation at ESMO Congress 2019 as Poster (suffix P or TiP) will be published online via the ESMO website at 00:05 CEST on Monday, 23 September 2019.
  2. Abstracts accepted for presentation at ESMO Congress 2019 as Proffered Paper (oral presentation) or Poster Discussion will be published online via the ESMO website at 00:05 CEST on Friday, 27 September 2019.
  3. All Late-breaking abstracts will be made public at the start of the official Congress session during which they are presented.
  4. Abstracts and Late-breaking abstracts selected for inclusion in the ESMO Press Programme will be published online according to a dedicated schedule. See paragraph below.
ESMO Press Programme: press releases schedule

Following abstracts are currently included in the ESMO Press Programme and will be accompanied by a press release.

Please note that for some them, the publication schedule may differ from the general one posted above.

Upon publication, direct link to the press releases will be added.

FPN Title Author name Embargo lift and press release distribution date/time
1629O_PR The price of added value for new anti-cancer drugs in France 2004-17 Marino Friday, 27 September 2019 at 00:05 CEST
1631PD_PR Clinical Benefit and Prices of Cancer Drugs in the US and Europe Vokinger Friday, 27 September 2019 at 00:05 CEST
LBA48_PR Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis Vale Friday, 27 September 2019 at 14:00 CEST
LBA49_PR Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): First Results from the RADICALS RT Randomised Controlled Trial (RCT) [NCT00541047] Parker Friday, 27 September 2019 at 14:00 CEST
LBA38_PR CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) Versus Sorafenib (SOR) as First-Line Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC) Yau Friday, 27 September 2019 at 14:00 CEST
LBA68_PR 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma Larkin Saturday, 28 September 2019 at 08:30 CEST
1983PD_PR Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria Ross Saturday, 28 September 2019 at 08:30 CEST
LBA15_PR A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary site (GEFCAPI 04) Fizazi Saturday, 28 September 2019 at 08:30 CEST
LBA30_PR Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration Taieb Saturday, 28 September 2019 at 14:45 CEST
LBA2_PR Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev Ray-Coquard Saturday, 28 September 2019 at 16:30 CEST
LBA4_PR Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis Peters Saturday, 28 September 2019 at 16:30 CEST
LBA5_PR Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis Ramalingam Saturday, 28 September 2019 at 16:30 CEST
LBA6_PR MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer Sledge Sunday, 29 September 2019 at 16:30 CEST
LBA7_PR Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) Slamon Sunday, 29 September 2019 at 16:30 CEST
LBA8_PR KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) Schmid Sunday, 29 September 2019 at 16:30 CEST
LBA81_PR Phase II/III blood-first assay screening trial (BFAST) in treatment-naïve NSCLC: initial results from the ALK+ cohort Gadgeel Monday, 30 September 2019 at 08:30 CEST
LBA91_PR A multicenter randomized phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma (MPM) – results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Popat Monday, 30 September 2019 at 10:15 CEST
LBA10_PR ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation Abou-Alfa Monday, 30 September 2019 at 16:30 CEST
LBA12_PR PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations Hussain Monday, 30 September 2019 at 16:30 CEST
LBA14_PR IMvigor130: efficacy and safety from a Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) Grande Monday, 30 September 2019 at 16:30 CEST

 

ESMO Press Conferences schedule

Times of press events may be subject to changes.

The Opening Press Conference and the Daily Press Briefings take place in the Press Conference Room, located in the Press & Media Centre - CC3, 1st Floor.

Abstracts presented in the press briefings are under embargo, content must not be disclosed until the official embargo lifts (please refer to the schedule above)

Date and time Media event Topics

Friday, 27 September
10:30-11:15

 

Opening Press Conference

Translating science into better cancer patient care​

ESMO President: Josep Tabernero, Spain
ESMO 2019 Press Officer: Pilar Garrido, Spain
ESMO 2019 Scientific Co-Chairs: Anton Berns, Netherlands and Jean-Yves Blay, France

Saturday, 28 September
07:30-08:15
Press briefing 1
Lung and Gynaecological cancers

Moderator and Commentator LBA5_PR: Pilar Garrido, Spain
Commentator LBA4_PR: Marina Garassino, Italy
Commentator LBA2_PR: Susana Banerjee, UK

  • LBA2_PR - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
    Isabelle Ray-Coquard, France
  • LBA4_PR - Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis
    Solange Peters, Switzerland
  • LBA5_PR - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
    Suresh Ramalingam, US
Sunday, 29 September
07:30-08:15
Press briefing 2
Breast cancer

Moderator and Commentator LBA8_PR: Giuseppe Curigliano, Italy
Commentator LBA6_PR and LBA7_PR: Nadia Harbeck, Germany

  • LBA6_PR - MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer
    George Sledge, US
  • LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
    Dennis Slamon, US
  • LBA8_PR - KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) Peter Schmid, UK
Monday, 30 September
07:30-08:15
Press briefing 3
Gastrointestinal and Genitourinary cancers

Moderator and Commentator LBA12_PR and LBA14_PR: Ignacio Duran, Spain
Commentator LBA10_PR: Angela Lamarca, UK

  • LBA10_PR - ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
    Ghassan Abou-Alfa, US
  • LBA12_PR - PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
    Maha Hussain, US
  • LBA14_PR - IMvigor130: efficacy and safety from a Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
    Enrique Grande, Spain

 

More information for media representatives

See all the ESMO press releases              ESMO on Twitter             

ESMO YouTube Channel ESMO Flickr Stream

Visit our YouTube Channel and get access to our latest videos.

Visit our  Flickr Stream and browse through our entire photo library

ESMO 2017 - Day 1

Policies

Related Links